Ronald Hunt

Ronald Hunt, listed as board member, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Harpoon Therapeutics, Inc., Iterum Therapeutics plc and Rallybio Corp. In total, 16 filings cover trades dated from 11 January 2021 to 6 August 2024.

No open-market sale appears; the market trades are 3 purchases worth €12.5M. The totals do not cover 1 filing with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 6 share grants and 6 option exercises.

1 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 12 August 2024: an option exercise, in Iterum Therapeutics plc. The most recent open-market purchase was published on 27 October 2023, 1,087 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.